Estrella Immunopharma Inc（ESLA）财务数据ESLAEstrella Immunopharma Inc

In the context of the broader market, ESLA competes directly with industry leaders such as QNTM and MRKR. With a market capitalization of $42.85M, it holds a leading position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against QNTM's N/A and MRKR's N/A. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent net losses, with a net income of -5,544,878 USD in Q2 2025 and a current ratio of only 0.20, indicating liquidity issues.